Entrada Therapeutics, Inc.
Business
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary endosomal escape vehicle (EEV) platform to deliver intracellular therapeutics. The company is advancing a portfolio of genetic medicines, including EEV-conjugated phosphorodiamidate morpholino oligomers (PMOs) for exon-skipping in Duchenne muscular dystrophy and partnered programs for myotonic dystrophy type 1. Entrada's programs target neuromuscular and inherited retinal diseases, with clinical candidates in the United States, European Union, and United Kingdom, and preclinical programs exploring ocular, metabolic, immunology and oncology indications.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 25 | 211 | 129 | — | — | |
| Research and development | 142 | 125 | 100 | 67 | 36 | |
| General and administrative | 41 | 38 | 32 | 31 | 15 | |
| Total operating expenses | 183 | 164 | 132 | 97 | 51 | |
| (Loss) income from operations | −158 | 47 | −3 | −97 | −51 | |
| Interest and other income | 15 | 19 | 15 | 3 | −31,000 | |
| Total other income | 15 | 19 | 15 | 3 | −31,000 | |
| (Loss) income before provision for income taxes | −143 | 67 | 12 | −95 | — | |
| Total income tax provision | 900,000 | 900,000 | −19 | 0 | — | |
| Net (loss) income | −144 | 66 | −7 | −95 | −51 | |
| Net (loss) income per share, basic (in dollars per share) | −3.47 | 1.76 | −0.2 | −3.02 | −8.16 | |
| Net (loss) income per share, diluted (in dollars per share) | −3.47 | 1.68 | −0.2 | −3.02 | −8.16 | |
| Weighted-average common shares outstanding, basic (in shares) | 41 | 37 | 33 | 31 | 6 | |
| Weighted-average common shares outstanding, diluted (in shares) | 41 | 39 | 33 | 31 | 6 | |
| Unrealized gain (loss) on marketable securities, net of tax of $0 | 695,000 | −238,000 | 2 | — | — | |
| Total other comprehensive income (loss) | 695,000 | −238,000 | 2 | −2 | 0 | |
| Total comprehensive (loss) income | −143 | 65 | −4 | −97 | −51 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 90 | 101 | 68 | 45 | 291 | |
| Marketable securities | 205 | 319 | 284 | 144 | 0 | |
| Restricted cash, current portion | 658,000 | 0 | — | — | — | |
| Collaboration receivable | 1 | 4 | 6 | 0 | — | |
| Prepaid expenses and other current assets | 9 | 16 | 12 | 21 | 8 | |
| Total current assets | 306 | 440 | 370 | 210 | 299 | |
| Property and equipment, net | 7 | 11 | 11 | 8 | 6 | |
| Restricted cash, net of current portion | 3 | 4 | 4 | 4 | 0 | |
| Right-of-use assets, operating leases | 60 | 71 | 81 | 25 | — | |
| Other non-current assets | 70,000 | 284,000 | 3 | 5 | 872,000 | |
| Total assets | 377 | 526 | 469 | 252 | 306 | |
| Accounts payable | 2 | 4 | 3 | 6 | 706,000 | |
| Accrued expenses and other current liabilities | 18 | 13 | 11 | 8 | 6 | |
| Income taxes payable | 0 | 667,000 | 4 | 0 | — | |
| Operating lease obligations, current portion | 4 | 8 | 8 | 8 | 0 | |
| Deferred revenue, current portion | 342,000 | 14 | 132 | 0 | — | |
| Total current liabilities | 24 | 39 | 159 | 22 | 7 | |
| Operating lease obligations, net of current portion | 47 | 52 | 60 | 18 | — | |
| Deferred revenue, net of current portion | 0 | 7 | 8 | 0 | — | |
| Total liabilities | 71 | 98 | 227 | 40 | 7 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common stock, par value $0.0001; 150,000,000 shares authorized; 38,284,221 shares issued and outstanding as of December 31, 2025 and 37,585,944 shares issued and 37,574,538 shares outstanding as of December 31, 2024 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 579 | 558 | 437 | 403 | 392 | |
| Accumulated other comprehensive income (loss) | 652,000 | −43,000 | 195,000 | −2 | 0 | |
| Accumulated deficit | −273 | −129 | −195 | −188 | −94 | |
| Total stockholders equity | 306 | 429 | 242 | 213 | 299 | |
| Total liabilities and stockholders equity | 377 | 526 | 469 | 252 | 306 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net (Loss) income | −144 | 66 | −7 | −95 | −51 | |
| Depreciation expense | 4 | 4 | 3 | 2 | 1 | |
| Stock-based compensation expense | 20 | 18 | 13 | 10 | 3 | |
| Net amortization of premium (accretion of discount) on marketable securities | −4 | −10 | −6 | 151,000 | 0 | |
| Collaboration receivable | 3 | 2 | −6 | 0 | — | |
| Prepaid expenses and other current assets | 8 | −4 | 9 | −14 | −7 | |
| Right-of-use assets, operating leases | 11 | 10 | 12 | 8 | — | |
| Other non-current assets | 214,000 | 3 | −12 | −4 | −331,000 | |
| Accounts payable | −2 | 991,000 | −3 | 5 | −715,000 | |
| Accrued expenses and other current liabilities | 5 | 2 | 4 | 2 | 4 | |
| Income taxes payable | −667,000 | −3 | 4 | 0 | — | |
| Deferred revenue | −20 | −120 | 140 | 0 | — | |
| Operating lease liabilities | −8 | −9 | −12 | −7 | — | |
| Net cash used in operating activities | −129 | −42 | 140 | −94 | −51 | |
| Purchases of property and equipment | −1 | −3 | −6 | −3 | −5 | |
| Purchases of marketable securities | −142 | −438 | −407 | −222 | 0 | |
| Maturities of marketable securities | 259 | 413 | 274 | 76 | 0 | |
| Net cash provided by (used in) investing activities | 117 | −28 | −138 | −149 | −5 | |
| Proceeds from exercise of stock options | 425,000 | 3 | 443,000 | 284,000 | 410,000 | |
| Proceeds from issuance of common stock under the employee stock purchase plan | 462,000 | 574,000 | 443,000 | — | — | |
| Net cash provided by financing activities | 887,000 | 103 | 21 | 479,000 | 307 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −11 | 34 | 22 | −242 | 252 | |
| Purchases of property and equipment included in accounts payable and accrued expenses | 0 | 560,000 | 208,000 | 88,000 | 155,000 | |
| Vesting of options early exercised subject to repurchase | 14,000 | 51,000 | 91,000 | 135,000 | 250,000 | |
| Cash paid for income taxes | 2 | 5 | 15 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Entrada Therapeutics, Inc.'s CIK number?
Entrada Therapeutics, Inc.'s SEC CIK number is 0001689375 (1689375). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Entrada Therapeutics, Inc.'s SEC filings?
All of Entrada Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Entrada Therapeutics, Inc. last report earnings?
Entrada Therapeutics, Inc. (TRDA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001689375-26-000027). This is Entrada Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Entrada Therapeutics, Inc.'s most recent earnings 8-K?
Entrada Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001689375-26-000027. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Entrada Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →